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Introduction 
Myelodysplastic syndromes (MDS) are a 
heterogeneous group of clonal  disorders of 
haematopoietic stem cells, characterised by ineffective 
haematopoiesis leading to peripheral cytopenias and 
hypercellular bone marrow, with increased propensity to 
progression to acute myeloid leukaemia. Anaemia is the 
most common symptom: it may precipitate symptoms 
in patients with cardiac disorders, thus affecting the 
patients' outcome.
Approved therapies, such as erythropoiesis-
stimulating agents, azacitidine, decitabine and 
lenalidomide are now available for patients who are 
ineligible for potentially curative haematopoietic stem 
cell transplantation. These former options can produce 
haematological improvement and enhance the quality 
of life of patients who previously would have received 
only supportive care.
In this context, supportive red blood cell transfusions 
represent a life-saving treatment for patients with chronic 
anaemia, in particular for those who do not respond or 
have a poor response to available treatments1. However, 
transfusions lead to iron overload, with an increased risk 
of associated comorbidity and mortality, independently 
of the underlying haematological disease, in relation to 
iron toxicity to cardiac, hepatic and endocrine cells. The 
management of iron overload is problematic because 
humans lack effective means to excrete excess iron.
Retrospective studies revealed that transfusion-
related iron toxicity is associated with reduced survival 
in MDS patients2. This is a particularly relevant problem 
in low-risk MDS patients, because of these patients' 
otherwise long-life expectancy. Adequate iron chelation 
therapy can, however, improve survival and may delay 
transformation into acute myeloid leukaemia3-6.
Iron chelation therapy is recommended in MDS to 
manage iron overload when the patient has, at least, 
elevated serum ferritin (SF), evidence of iron-related 
organ dysfunction or is receiving chronic red blood cell 
(RBC) transfusions. Guidelines from the Italian Society 
of Haematology recommend iron chelation therapy 
with deferasirox for the treatment of MDS patients with 
low/intermediate-1 risk (according to the International 
Prognostic Scoring Scale, IPSS) after they have received 
at least 20 units of packed RBC5.
It is evident from controlled clinical trials, and 
confirmed by real-life experience7, that iron overload in 
many MDS patients is often not adequately managed4.
Iron chelation therapy should be considered in all 
patients who require long-term RBC transfusions while 
it may not be needed in patients with MDS or other 
acquired refractory anaemias who have an estimated 
survival of less than 1 year.
Ideally, chelation therapy should be initiated 
prophylactically, before clinically significant iron 
accumulation has occurred. Treatment should begin 
when patients have received between 10 and 20 units 
of RBC. Patients who have already undergone repeated 
transfusions without sufficient chelation can also 
be successfully treated, but they may require more 
intensive chelating regimens. Iron chelation therapy 
is recommended by several treatment guidelines for 
patients who have a low or intermediate-1 IPSS risk 
and SF >1,000-2,000 ng/mL, depending on transfusion 
requirements.
Evaluation of the patient before the initiation or 
adjustment of iron chelation therapy should include 
a detailed characterisation of the underlying disorder, 
with thorough documentation of the transfusion and 
chelation history, determination of body iron load by 
measurement of hepatic iron and SF, estimation of the 
rate of transfusional iron loading, and assessment of 
cardiac iron deposition8. 
Until recently, desferoxamine and deferiprone were 
the only drugs available for iron chelation therapy and 
neither was well tolerated by patients. 
Deferoxamine was developed more than 40 years 
ago and, due to its pharmakokinetic properties, in order 
to be effective, must be administered subcutaneously 
or intravenously, usually with a portable pump, as a 
slow infusion over 8-12 hours/day, 5-7 days/week, 
often resulting in poor compliance. Subcutaneous 
administration is preferred, except in patients 
with severe cardiac iron deposition, for whom 
continuous intravenous deferoxamine is recommended. 
This regimen is contraindicated in patients with 
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thrombocytopenia and the inconvenience often results 
in low compliance9-11.
Deferiprone is not approved or recommended for 
MDS, as it can cause neutropenia and agranulocytosis.
Deferasirox is a once-daily orally administered iron 
chelator, with established dose-dependent efficacy, 
approved for the treatment of transfusional iron overload 
in both adult and paediatric patients with transfusion-
dependent anaemia. The initial dose of 10 mg/kg can 
be increased to 20-30 mg/kg based on the degree of 
iron load, concentration of SF and extent of iron-related 
organ damage12. The efficacy and safety of deferasirox 
have been evaluated in patients with β-thalassaemia 
and a wide range of other disorders, including MDS, 
sickle cell disease, aplastic anaemia, Diamond-Blackfan 
anaemia, and other rare anaemias13. In vivo studies in 
acute myeloid leukaemia and MDS cell lines showed 
that deferasirox is a potent nuclear factor-kB inhibitor, 
which may partly explain the reports regarding its ability 
to produce haematological improvements14,15. In addition 
to reducing key indicators of total body iron level (SF, 
liver iron concentration, and toxic labile plasma iron), 
deferasirox has also been shown to remove cardiac iron 
and prevent further cardiac iron accumulation. It has an 
acceptable safety profile: the most commonly reported 
side effects have been non-progressive changes in serum 
creatinine levels, gastrointestinal disturbances and skin 
rashes, with significant increases in alanine transaminase 
value after 12 months of treatment being possible, in direct 
correlation with the dose administered7. Because of its 
potential hepatotoxicity, it is usually not recommended 
for patients with known liver disease.
Nowadays, most patients requiring iron chelation 
therapy opt for deferasirox because of the convenience 
of its oral administration, while deferoxamine, which 
has been proven to reverse iron-induced heart disease 
and increase long-term survival16, may be indicated if 
deferasirox is ineffective, and it may be favoured for 
severe iron overload, especially with cardiac involvement. 
Deferasirox may be better in patients who are unable 
to tolerate subcutaneous infusions of deferoxamine 
and it may also be an alternative to deferoxamine after 
successful clearance of cardiac iron. 
To our knowledge, the possibility of iron chelation 
therapy with a combination of deferasirox and 
deferoxamine has been reported only in patients with 
β-thalasssaemia17-20. There do not appear to be any data 
on the use of this combination in MDS patients with liver 
disease. We describe here the first patient affected by 
MDS and chronic liver disease in whom combined iron 
chelation therapy was successfully employed.
Case report
A 62-year old Caucasian man was first seen in our 
Division for anaemia. He was diagnosed as having 
MDS-refractory anaemia (low IPSS risk), and hepatitis 
C virus-correlated liver cirrhosis (Child-Pugh class B) 
with signs of portal hypertension (portal vein 14.6 mm, 
splenic vein 14 mm, normal mesenteric vein), and severe 
splenomegaly (longitudinal diameter 205 mm). Liver 
function tests at the diagnosis of MDS were: serum 
albumin 3.2 g/dL, normal coagulation profile, total/
direct bilirubin 1.01/0.69; aspartate transaminase 38 
U/L (normal values <40 U/L), alanine transaminase 60 
U/L (normal values <40 U/L). The patient was initially 
treated with an erythropoiesis-stimulating agent (30,000 
U/week), without success for 6 months, which was then 
withdrawn, and he continued treatment with only RBC 
transfusions, requiring two packs/month. Iron chelation 
therapy was started when he had a SF of 700 ng/mL 
(normal values 30-400 ng/mL): deferoxamine was given 
(starting dose 15 mg/kg/day, for 5 days/week, increased 
up to 25 mg/kg/day, for 5 days/week), in consideration 
of the patient's pre-existing hepatic disease. However, 
the patient was unable to take the drug correctly and 
his transfusion needs increased to two packs of RBC/
week, with his SF exceeding 6,000 ng/mL (Figure 1), 
after 12 months of transfusion treatment. At that time, 
Figure 1 - Time course of serum ferritin (normal values: 30-400 ng/dL) and haemoglobin concentrations.
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deferasirox was started (Table I) at the dose of 10 mg/
kg/day, after a thorough investigation of the patient's 
hepatic, renal and cardiac function. After 3 months, 
neither SF nor other biochemical parameters had 
changed. The dose of deferasirox was then gradually 
increased to 30 mg/kg/die after 2 months, without 
evidence of liver damage. After 5 months of a full 
dose of deferasirox, the patient's SF concentration was 
5,098 ng/mL.
Taking into consideration all risks related to secondary 
haemochromatosis, after informed consent, combined 
iron chelation therapy with deferasirox (30 mg/kg/die) 
and deferoxamine (25 mg/kg/day for 5 days/week) was 
started. After 3 months the patient's SF had decreased 
to 3,000 ng/mL. In the meantime, his haemoglobin 
concentration decreased significantly, so he had to be given 
two packs of RBC/week. After 2 years of combined therapy, 
his SF concentration was stable under 3,000 ng/mL and his 
transfusion requirements gradually decreased (Figure 1). 
No adverse events were observed and regular monitoring 
of hepatic (Figure 2), renal and cardiac function did not 
show any alterations. After 4 years of transfusions and 
combined iron chelation therapy, the patient died from 
acute respiratory distress syndrome.
Discussion 
Supportive care of MDS patients is based on RBC 
transfusions, with management of iron overload being 
an essential, but sometimes overlooked, part of the 
treatment. In recent years, better understanding of the 
biological consequences of secondary haemosiderosis 
in MDS has suggested that iron chelation therapy should 
be started promptly to prevent serious clinical sequelae 
in patients with a long life-expectancy. Retrospective 
analyses indicated that iron overloading has an impact on 
the outcome of MDS patients and suggested that chelation 
therapy could improve patients' overall survival.
Until recently, desferoxamine and deferiprone were 
the only drugs available for the treatment of transfusional 
iron overload, but deferasirox is changing the clinical 
scenario of iron chelation therapy.
Deferasirox is a once-daily orally administered iron 
chelator, with established dose-dependent efficacy, 
approved for the treatment of transfusional iron overload 
in both adult and paediatric patients with transfusion-
dependent anaemia. The drug has an acceptable safety 
profile, with the most common side effects reported 
being non-progressive changes in serum creatinine 
levels, gastrointestinal disturbances, and skin rash, and 
dose-related hepato-toxicity. 
Deferasirox may allow effective iron chelation 
therapy in patients intolerant to subcutaneous infusions 
of deferoxamine.
In our case, the combination of deferasirox and 
deferoxamine had significant effects on iron overload, 
Figure 2 -  Time course of liver function parameters: aspartate transaminase (AST, normal values <40 U/L) and alanine 
transaminase (ALT, normal values <40 U/L).
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 Table I - Characteristics of deferoxamine and deferasirox8.
Variable Deferoxamine Deferasirox 
Chelator-iron 
complex
Hexadentate, 
1:1 complex
Tridentate, 
2:1 complex
Usual dose 25-50 mg/kg/day 20-40 mg/kg/day
Administration Subcutaneous or 
intravenous, 8-10 h/day, 
5-7 days/week
Oral, once daily
Plasma half-life 20-30 min 8-16 hr
Route of 
elimination
Biliary and urinary Predominantly biliary
Regulatory 
approval
Approved in USA, 
Canada, Europe and 
other countries
Approved in USA, 
Canada, Europe and 
other countries
Indication Transfusional iron 
overload
Transfusional iron 
overload
Adverse effects Irritation at the infusion 
site, ocular and auditory 
disturbances, growth 
retardation and skeletal 
changes, allergy, 
respiratory distress 
syndrome with higher-
than-recommended doses
Gastrointestinal 
disturbances, rash, 
increase in serum 
creatinine level; 
potential foetal renal 
and hepatic impairment 
or failure, gastrointestinal 
haemorrhage© 
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and proved to be safe in a patient with hepatitis C virus-
correlated liver cirrhosis. The patient complied well with 
the treatment, had a good quality of life, had no side 
effects and did not require hospitalisation. Moreover, 
as reported in literature, deferasirox can also improve 
haematological parameters: our patient had a decrease in 
transfusional needs during treatment, which could have 
been related to the deferasirox treatment2,6,14. 
In our opinion, if deferasirox alone is not able to 
reduce iron overload rapidly, combined treatment with 
deferoxamine should be considered a safe and useful 
therapeutic choice, in selected patients, although our 
preliminary observations need to be validated by 
controlled clinical trials. 
Authorship contributions
CC, FP and LC participated in the conception and 
design of the study, data analysis and interpretation, 
drafting the article and revising it critically for important 
intellectual content, and approved the final version for 
publication giving final approval for publication. CC 
also collected the data and is responsible for the overall 
content as guarantor. 
GC, SA, RDP, NP and MP participated in the 
conception and design of the study, data analysis 
and interpretation, and approved the final version for 
publication.
Keywords: deferasirox, deferoxamine, iron overload, 
iron chelation, myelodysplastic syndromes.
The Authors declare no conflicts of interest.
References
1) Malcovati L, Hellström-Lindberg E, Bowen D, et al. Diagnosis 
and treatment of primary myelodysplastic syndromes in adults: 
recommendations from the European LeukemiaNet. Blood 
2013; 122: 2943-64.
2) Improta S, Villa MR, Volpe A, et al. Transfusion-dependent 
low-risk myelodysplastic patients receiving deferasirox: long-
term follow-up. Oncol Lett 2013; 6; 1774-8.
3) Neukirchen J, Fox F, Kündgen A, et al. Improved survival in 
MDS patients receiving iron chelation therapy – a matched 
pair analysis of 188 patients from the Dusseldorf MDS registry. 
Leuk Res 2012; 36; 1067-70.
4) Rose C, Brechignac S, Vassilief D, et al. Does iron chelation 
therapy improve survival in regularly transfused lower risk 
MDS patients? A multicenter study by the GFM (Groupe 
Francophone des Myelodysplasies). Leuk Res 2010; 34; 
864-70.
5) Santini V, Alessandrino PE, Angelucci E, et al. Clinical 
management of myelodysplastic syndromes: update of SIE, 
SIES, GITMO practice guidelines. Leuk Res 2010; 34; 
1576-88.
6) Malcovati L. Impact on transfusion dependency and secondary 
iron overload on the survival of patients with myelodysplastic 
syndromes. Leuk Res 2007: 31 (Suppl 3): S2-6.
7) Breccia M, Alimena G. Efficacy and safety of deferasirox in 
myelodysplastic syndromes. Ann Hematol 2013; 92: 863-70.
8) Brittenham GM. Iron-chelating therapy for transfusional iron 
overload. N Engl J Med 2011; 364: 146-56.
9) Nisbet-Brown E, Olivieri NF, Giardina PJ, et al. Effectiveness 
and safety of ICL670 in iron-loaded patients with thalassemia: 
a randomised, double-blind, placebo-controlled, dose-
escalation trial. Lancet 2003; 361: 1597-602.
10) Cohen AR. Compassionate use of deferiprone for patients with 
thalassemia and iron-induced heart disease. ClinicalTrials.gov 
identifier n. NCT00293098.
11) Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac 
morbidity and mortality in deferoxamine- or deferiprone-
treated patients with thalassemia major. Blood 2006; 107: 
3733-7
12) Gattermann N, Finelli C, Porta MD et al. Deferasirox in iron-
overload patients with transfusion dependent myelodysplastic 
syndromes: results from the large 1-year EPIC study. Leuk 
Res 2101; 34: 1143-50.
13) Porter J, Galanello R, Saglio G, et al. Relative response 
of patients with myelodysplastic syndromes and other 
transfusion-dependent anemias to deferasirox (ICL670): a 
1-year prospective study. Eur J Haematol 2008; 80: 168-76.
14) Gattermann N, Finelli C, Della Porta M, et al. Hematologic 
responses with deferasirox therapy in transfusion-dependent 
myelodysplastic syndromes patients. Haematologica 2012; 
97: 1364-71.
15) List AF, Baer MR, Steensma DP, et al. Deferasirox reduces 
serum ferritin and labile plasma iron in RBC transfusion-
dependent patients with myelodysplastic syndrome. J Clin 
Oncol 2012; 30: 2134-9. 
16) Davis BA, Porter JB. Long-term outcome of continuous 
24-hour deferoxamine infusion via indwelling intravenous 
catheters in high-risk beta-thalassemia. Blood 2000; 95: 
1229-36.
17) Jetsrisuparb A, Komvilaisak P, Wiangnon S, Jetsrisuparb C. 
Retrospective study on the combination of desferrioxamine 
and deferasirox for treatment of iron-overloaded thalassemic 
patients: first evidence of more than 2 years. J Pediatr Hematol 
Oncol 2010; 32: 400-3.
18) Lal A, Porter J, Sweeters N, et al. Combined chelation therapy 
with deferasirox and deferoxamine in thalassemia. Blood Cells 
Mol Dis 2013; 50: 99-104.
19) Voskaridou E, Komninaka V, Karavas A, et al. Combination 
therapy of deferasirox and deferoxamine shows significant 
improvement in markers of iron overload in a patient with 
β-thalassemia mayor and severe iron burden. Transfusion 
2014; 54: 646-9.
20) Cassinerio E, Orofino N, Roghi A, et al. Combination 
of deferasirox and deferoxamine in clinical practice: an 
alternative scheme of chelation in thalassemia major patients. 
Blood Cells Mol Dis 2014; 53: 164-7.
© 
SIM
TI 
Se
r i
zi 
Srl
All rights reserved - For personal use only 
No other use without premission
